Conclusion
In the realm of paediatric oncology care, a holistic approach is
essential to effectively address drug wastage and the associated
financial implications. One strategy involves encouraging pharmaceutical
manufacturers to tailor vial sizes to meet the unique needs of the
paediatric population. Additionally, exploring the feasibility of
multi-dose vials with extended stability could prove advantageous.
Healthcare providers can also play a crucial role by developing
institution-specific protocols for dose rounding and vial sharing,
informed by the stability data provided in the package insert. This
balanced approach can help optimize resources and improve the efficiency
of paediatric oncology drug administration.
Ethical Approval: The study was approved by Institutional
Ethics Committee(IEC) number 381/19 dated 28/10/2019
Acknowledgment: We acknowledge Department of paediatric for
their constant support
Funding: None
Competing interests: There are no competing interest to
declare.
Data Availability Statement: The data that support the findings
of this study are available from the corresponding author upon
reasonable request.